Notably, the clinical-stage FAK inhibitor defactinib, when combined with sorafenib, exhibited significant synergistic effects in HCC cell lines, HCC organoids, and cell line–derived xenograft models. This evidence concerns the gene PTK2 and hepatocellular carcinoma.